BREATHE California of Los Angeles County is a non-profit, non-partisan organization that promotes clean air and healthy lungs through education, research, technology and advocacy. Our goal is to promote community health services through prevention, education and early diagnosis for low-income underserved individuals suffering from respiratory related chronic conditions such as asthma, lung disease and chronic obstructive pulmonary disease (COPD) which is now the third leading cause of death in the United States. While COPD continues to be on the rise, it remains one of the most poorly funded areas of medical treatment, advocacy and research. COPD has now reached epidemic proportions with more than 15 million Americans diagnosed with COPD and of that number, more than 300,000 Los Angeles residents having been diagnosed with the disease.
March 7, 2018
BREATHE LA Open House
Join us as we showcase our programs and welcome our new President & CEO, Marc Carrel.
Chronic Obstructive Pulmonary Disease (COPD) is a lung disease that progresses slowly over time, making it difficult to breathe. In people who have COPD, the airways, or tubes that carry air from the nose and mouth into the lungs, are partially blocked – either because of thickening and mucus, or because the airways are floppy and collapse, or both. It is the third leading cause of death in the United States, killing more than 120,000 Americans each year; that is one death every four minutes
*COPD Population Screener™ copyright 2004 QualityMetric Incorporated. All Rights Reserved.
COPD Population Screener™ is a trademark of QualityMetric Incorporated.
Sources and Usage Guidelines
The screener is validated for use in the United States and was published in the Journal of Chronic Obstructive Pulmonary Disease, April 2008, Martinez, F. J., Raczek, A. E., Seifer, F. D., Conoscenti, C. S., Curtice, T. G. & D’Eletto, T., et al. (2008). Development and Initial Validation of a Self-Scored COPD Population Screener Questionnaire (COPD-PS). COPD: Journal of Chronic Obstructive Pulmonary Disease, 5:2, 85-95.